<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4198">
  <stage>Registered</stage>
  <submitdate>11/11/2013</submitdate>
  <approvaldate>11/11/2013</approvaldate>
  <nctid>NCT01992276</nctid>
  <trial_identification>
    <studytitle>Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection</studytitle>
    <scientifictitle>Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of CR8020 and CR6261 in Hospitalized Patients With Influenza A Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-003341-41</secondaryid>
    <secondaryid>CR102576</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - CR8020
Other interventions - CR6261
Other interventions - Placebo

Experimental: CR8020 - Investigational monoclonal antibody against influenza A viruses

Experimental: CR6261 - Investigational monoclonal antibody against influenza A viruses

Placebo Comparator: Placebo - Dextrose: 5% in water


Other interventions: CR8020
30 mg/kg administered as a single 2-hour intravenous infusion on Day 1

Other interventions: CR6261
30 mg/kg administered as a single 2-hour intravenous infusion on Day 1

Other interventions: Placebo
Administered as a single 2-hour intravenous infusion on Day 1

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of decline in quantitative viral load</outcome>
      <timepoint>Baseline to Day 8</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical improvement - Daily influenza symptoms and signs:
Four domains from the Influenza Intensity and Impact Questionnaire will be evaluated (scored 0-3: none, mild, moderate, severe):
-Influenza symptoms (respiratory and systemic domains Impact on daily activities Impact on emotions Impact on others</outcome>
      <timepoint>Baseline to Day 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of decline in quantitative viral load (subjects not intubated at baseline)</outcome>
      <timepoint>Baseline to Day 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of decline in quantitative viral load (subjects intubated at baseline)</outcome>
      <timepoint>Baseline to Day 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of decline in quantitative viral load</outcome>
      <timepoint>Baseline to Day 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events</outcome>
      <timepoint>Baseline to Day 116</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of serious adverse events</outcome>
      <timepoint>Baseline to Day 116</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the curve of viral load</outcome>
      <timepoint>Baseline to Day 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical course for ICU patients</outcome>
      <timepoint>Baseline to Day 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of hospital stay</outcome>
      <timepoint>The duration of hospital stay, an expected average of 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Survival times - Survival times measured from randomization to time of death</outcome>
      <timepoint>Baseline to Day 116</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Participant requires hospitalization/ Each participant or his or her legally acceptable
        representative must sign an informed consent form/ Participant must be able to start the
        infusion within 36 hours from the time the screening specimen was collected/ A woman must
        either be not of childbearing potential or of childbearing potential and agrees to practice
        two forms of highly effective method of birth control/ A woman of childbearing potential
        must have a negative serum (beta human chorionic gonadotropin [beta hCG]) at screening/ A
        man who is sexually active with a woman of childbearing potential and has not had a
        vasectomy must agree to use a barrier method of birth control/</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Participant is a female who is pregnant or breastfeeding/ Participant undergoing peritoneal
        dialysis, hemodialysis or hemofiltration/ Participant has presence of any pre-existing
        illness that, in the opinion of the investigator, would place the participant at an
        unreasonably increased risk through participation in this study/ Participant has prior
        treatment with an experimental mAb; or receipt of IgG within 3 months or on chronic mAb
        treatment prior to enrollment/ Participant has known or suspected hypersensitivity to any
        of the CR8020 or CR6261 excipients (sucrose, L-histidine L-histidine monohydrochloride,
        polysorbate 20)/ Participant received an investigational product (including investigational
        vaccines) or used an investigational medical device within 60 days before the planned start
        of treatment, is currently enrolled in an interventional investigational study, or is an
        employee of the investigational site/</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/12/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Parkville - Vic</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Parkville - Vic</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Belo Horizonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Campinas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Curitiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Passo Fundo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Ribeirão Preto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Jose Do Rio Preto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto N/A</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>St Priest-En-Jarez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Donaustauf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Potsdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Apeldoorn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Benoni</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Córdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Elche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>San Sebastian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santander N/A</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Tarragona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malmö</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Crucell Holland BV</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Division of Microbiology and Infectious Diseases (DMID)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Institutes of Health (NIH)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the rate of decline in quantitative viral load
      measured in hospitalized patients with Influenza A infection</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01992276</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Crucell Holland BV Clinical Trial</name>
      <address>Crucell Holland BV</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>